Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

Gitte Dam; Henning Grønbæk; Anna Sundlöv; Johan Botling; Anders Sundin; Rene Horsleben Petersen; Staffan Welin; Espen Thiis Evensen; Halfdan Sorbye; Elizaveta Tabaksblat; Anne Kirstine Arveschoug; Jann Mortensen; Andreas Kjaer; Ulrich Knigge; Eva Tiensuu Janson; Seppo W. Langer

doi:10.1080/0284186X.2023.2212411

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

Gitte Dam, Henning Grønbæk, Anna Sundlöv, Johan Botling, Anders Sundin, Rene Horsleben Petersen, Staffan Welin, Espen Thiis Evensen, Halfdan Sorbye, Elizaveta Tabaksblat, Anne Kirstine Arveschoug, Jann Mortensen, Andreas Kjaer, Ulrich Knigge, Eva Tiensuu Janson, Seppo W. Langer

Medical oncology

Research output: Contribution to journal › Review article › peer-review

Abstract

Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group’s current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. Small cell lung carcinoma (SCLC) is not included in these guidelines.

Original language	English
Pages (from-to)	431-437
Number of pages	7
Journal	Acta Oncologica
Volume	62
Issue number	5
DOIs	https://doi.org/10.1080/0284186X.2023.2212411
Publication status	Published - 2023

Subject classification (UKÄ)

Cancer and Oncology

Free keywords

bronchopulmonary neoplasm
diagnosis
Lung
neuroendocrine carcinoma
neuroendocrine neoplasm
treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/0284186X.2023.2212411

Cite this

Dam, G., Grønbæk, H., Sundlöv, A., Botling, J., Sundin, A., Petersen, R. H., Welin, S., Evensen, E. T., Sorbye, H., Tabaksblat, E., Arveschoug, A. K., Mortensen, J., Kjaer, A., Knigge, U., Tiensuu Janson, E., & Langer, S. W. (2023). Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Acta Oncologica, 62(5), 431-437. https://doi.org/10.1080/0284186X.2023.2212411

@article{4bc1d6768f8f4e33ace4d7874fb02f46,

title = "Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms",

abstract = "Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group{\textquoteright}s current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. Small cell lung carcinoma (SCLC) is not included in these guidelines.",

keywords = "bronchopulmonary neoplasm, diagnosis, Lung, neuroendocrine carcinoma, neuroendocrine neoplasm, treatment",

author = "Gitte Dam and Henning Gr{\o}nb{\ae}k and Anna Sundl{\"o}v and Johan Botling and Anders Sundin and Petersen, {Rene Horsleben} and Staffan Welin and Evensen, {Espen Thiis} and Halfdan Sorbye and Elizaveta Tabaksblat and Arveschoug, {Anne Kirstine} and Jann Mortensen and Andreas Kjaer and Ulrich Knigge and {Tiensuu Janson}, Eva and Langer, {Seppo W.}",

year = "2023",

doi = "10.1080/0284186X.2023.2212411",

language = "English",

volume = "62",

pages = "431--437",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Taylor & Francis",

number = "5",

}

Dam, G, Grønbæk, H, Sundlöv, A, Botling, J, Sundin, A, Petersen, RH, Welin, S, Evensen, ET, Sorbye, H, Tabaksblat, E, Arveschoug, AK, Mortensen, J, Kjaer, A, Knigge, U, Tiensuu Janson, E & Langer, SW 2023, 'Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms', Acta Oncologica, vol. 62, no. 5, pp. 431-437. https://doi.org/10.1080/0284186X.2023.2212411

TY - JOUR

T1 - Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

AU - Dam, Gitte

AU - Grønbæk, Henning

AU - Sundlöv, Anna

AU - Botling, Johan

AU - Sundin, Anders

AU - Petersen, Rene Horsleben

AU - Welin, Staffan

AU - Evensen, Espen Thiis

AU - Sorbye, Halfdan

AU - Tabaksblat, Elizaveta

AU - Arveschoug, Anne Kirstine

AU - Mortensen, Jann

AU - Kjaer, Andreas

AU - Knigge, Ulrich

AU - Tiensuu Janson, Eva

AU - Langer, Seppo W.

PY - 2023

Y1 - 2023

N2 - Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group’s current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. Small cell lung carcinoma (SCLC) is not included in these guidelines.

AB - Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group’s current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. Small cell lung carcinoma (SCLC) is not included in these guidelines.

KW - bronchopulmonary neoplasm

KW - diagnosis

KW - Lung

KW - neuroendocrine carcinoma

KW - neuroendocrine neoplasm

KW - treatment

U2 - 10.1080/0284186X.2023.2212411

DO - 10.1080/0284186X.2023.2212411

M3 - Review article

C2 - 37194281

AN - SCOPUS:85159609658

SN - 0284-186X

VL - 62

SP - 431

EP - 437

JO - Acta Oncologica

JF - Acta Oncologica

IS - 5

ER -

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

Abstract

Subject classification (UKÄ)

Free keywords

UN SDGs

Access to Document

Fingerprint

Cite this